SCHEMBL1447152

SCHEMBL1447152

Cc1cc(C(F)(F)F)c(-c2ncnc(-c3cc(O)c(O)c([N+](=O)[O-])c3)n2)c(-c2ccccc2)[n+]1[O-]

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
COMT P21964 2/20 0.39
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
TTR P02766 3/20 0.34
ABCC1 P33527 3/20 0.34
ABCG2 Q9UNQ0 2/20 0.34
RAB9A P51151 4/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
NPC1 O15118 3/20 0.33
PAX8 Q06710 1/20 0.33
KDM4E B2RXH2 3/20 0.33
MAPT P10636 3/20 0.33
GPR35 Q9HC97 2/20 0.33
ALDH1A1 P00352 2/20 0.33
TP53 P04637 2/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 2/20 0.33
GMNN O75496 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2689670 0.89 COMT (0.38) COMTCRHBPCRHR2TTRABCC1
SCHEMBL1448018 0.87 COMT (0.44) COMTCRHBPCRHR2TTRMEN1
SCHEMBL1446692 0.86 COMT (0.54) COMTCRHBPCRHR2RAB9ANPC1
SCHEMBL1447379 0.85 COMT (0.49) COMTCRHBPCRHR2RAB9ANPC1
SCHEMBL3588239 0.85 CRHBP (0.40) COMTCRHBPCRHR2TTRABCC1
SCHEMBL1447183 0.85 COMT (0.38) COMTCRHBPCRHR2TTRABCC1
SCHEMBL1446999 0.82 MEN1 (0.41) COMTCRHBPCRHR2TTRRAB9A
SCHEMBL1447021 0.82 THRB (0.41) COMTCRHBPCRHR2TTRRAB9A
SCHEMBL1447648 0.81 EIF4E (0.42) COMTCRHBPCRHR2MEN1KMT2A
SCHEMBL1447015 0.81 COMT (0.39) COMTCRHBPCRHR2TTRABCC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220388999-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS BIAL PORTELA & CA SA (PT) 2022-12-08 US disclosed
US-20200102295-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS BIAL - PORTELA & CA, S.A. (PT) 2020-04-02 US disclosed
US-10336740-B2 Nitrocatechol derivatives as COMT inhibitors BIAL—PORTELA & CA, S.A. (PT) 2019-07-02 US disclosed
US-20170362213-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS PORTELA & COMPANHIA, S.A. (PT) 2017-12-21 US disclosed
US-9550759-B2 Nitrocatechol derivatives as COMT inhibitors BIAL—PORTELA & CA, S.A. (PT) 2017-01-24 US disclosed
EP-1907382-B1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS BIAL PORTELA & CA SA (PT) 2015-05-27 EP disclosed
US-20150072977-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS BIAL - PORTELA & CA, S.A. (PT) 2015-03-12 US disclosed
US-8907099-B2 Nitrocatechol derivatives as COMT inhibitors BIAL-PORTELA & CA, S.A. (PT) 2014-12-09 US disclosed
US-20120196904-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS PORTELA & CA., S.A. (PT) 2012-08-02 US disclosed
US-8168793-B2 Nitrocatechol derivatives as COMT inhibitors PORTELA & CA., S.A. (PT) 2012-05-01 US disclosed
EP-2301934-A1 Nitrocatechol derivatives as COMT inhibitors BIAL - Portela & Ca., S.A. (PT) 2011-03-30 EP disclosed
US-20090054437-A1 Nitrocatechol Derivatives as Comt Inhibitors PORTELA & CA., S.A. (PT) 2009-02-26 US disclosed
EP-1907382-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS Portela & C.A. S.A (PT) 2008-04-09 EP disclosed
WO-2007013830-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS PORTELA & CA. S.A. (PT) 2007-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362213-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 COMT 1/4885CRHBP 1863/4885CRHR2 1499/4885
US-20150072977-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 COMT 1/4885CRHBP 1863/4885CRHR2 1499/4885
US-20220388999-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 COMT 1/4885CRHBP 1626/4885CRHR2 1245/4885
US-20090054437-A1 Nitrocatechol Derivatives as Comt Inhibitors COMT, PNMT, OPRK1 COMT 1/4885CRHBP 1863/4885CRHR2 1499/4885
US-10336740-B2 Nitrocatechol derivatives as COMT inhibitors COMT, PNMT, OPRK1 COMT 1/4885CRHBP 1863/4885CRHR2 1499/4885
US-20200102295-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 COMT 1/4885CRHBP 1626/4885CRHR2 1245/4885
US-20120196904-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 COMT 1/4885CRHBP 1863/4885CRHR2 1499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.